In its annual briefing for Wall Streeters, the drugmaker offers sobering forecasts for beside year and, meanwhile, testament proclaim a loss this year thanks to bounteous than $4 billion in charges stemming from its $6.5 billion deal to acquire ImClone Systems. "The pharmaceutical industry, " Lilly ceo John Lechleiter reminds the crowd, " continues to face hefty challenges." Ensuing year, revenue will build in the low unmarried digits, and the drugmaker pointed to the Cymbalta antidepressant, the Cialis impotence pellet and its Prasugrel blood thinner, for which Lilly hopes to killing FDA approval after year after new delays (back story).

Full text